Stocks
Perspective Therapeutics, Inc.CATX
AMEXHealthcareBiotechnology$1.61
Price as of · delayed, not real-time
A clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer, with a lead candidate in trials for neuroendocrine tumors. Its proprietary isotope production and delivery platform differentiates it in the emerging radiopharma space, and investors track it for potential readouts and regulatory milestones.
52W Range: $1.58-$6.16
Congressional Interest in Perspective Therapeutics, Inc. (CATX)
No congressional trades have been disclosed for Perspective Therapeutics, Inc. (CATX) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading CATX?
No congressional trades found for this stock.